Aragen partners with Renaissance Pharma to manufacture rare disease therapy
By
Josh Abbott
1mo agoen
Source
bioprocessintl.comAragen partners with Renaissance Pharma to manufacture rare disease therapybioprocessintl.comThe biotech firm produced its first commercial-scale GMP batches of lead-candidate Daretabart.
You might also wanna read
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·1d ago
CRISPR’s next act: the companies editing the epigenome to treat disease
go.nature.com·6d ago
Experimental Novartis radiopharma drug shows promise in early study
reuters.com·1mo ago
How Taxpayer-Funded Research Led to a $2 Million Gene Therapy: The Zolgensma Story
This investigative piece traces the development of Zolgensma, a gene therapy for spinal muscular atrophy that became the world's most expens
propublica.org·1d ago
Alp Bio's AI platform predicts immune reactions to biologic drugs earlier in development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
vist.ly·12d ago
Alp Bio's AI platform predicts immune reactions to biologic drugs in early development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
vist.ly·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.